SBI, Theragnostics ink oral cancer technology deal
Molecular radiotherapy developer Theragnostics and Summit Biomedical Imaging...Read more on AuntMinnie.comRelated Reading: GE, Theragnostics partner on PSMA agent Theragnostics inks AstraZeneca agreement (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 23, 2020 Category: Radiology Source Type: news

Mouth cancer symptoms: The taste in your mouth that may signal the deadly disease
MOUTH cancer can develop in most parts of the mouth so the symptoms can vary. One telltale sign is a certain taste in your mouth - have you tasted this? (Source: Daily Express - Health)
Source: Daily Express - Health - September 23, 2020 Category: Consumer Health News Source Type: news

What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

How Cancer Shaped Justice Ruth Bader Ginsburg ’s Life and Work
The name Ruth Bader Ginsburg became almost synonymous with strength and stamina as she rose to prominence in judicial and feminist circles throughout her long career. Famously nicknamed the Notorious RBG and known for her grueling fitness regimen, the late Supreme Court justice also struggled with cancer and other health issues for the better part of her time on the bench — culminating with her death on Sept. 18 at the age of 87 of complications from metastatic pancreatic cancer. Ginsburg’s health issues became public in 1999, six years after her appointment to the Supreme Court, when she had surgery for early-...
Source: TIME: Health - September 19, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime remembrance Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

BrainCool Announces Statistically Significant Late-Breaking Clinical Data at ESMO Virtual Congress 2020
Cooral® System Intra-Oral Cooling Device Prevents Oral Mucositis (OM) A New Standard is Set for Preventing One of the Severest Side-Effects of Cancer Treatment LUND, Sweden, Sept. 18, 2020 -- (Healthcare Sales & Marketing Network) -- BrainCool A... Devices, Oncology BrainCool, Cooral System, hypothermia, oral mucositis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Media News - September 9, 2020 Category: Pharmaceuticals Source Type: news

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)
Basel, 9 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of an innovative Phase III clinical trial programme for its investigational medicine fenebrutinib in multiple sclerosis (MS), along with a higher-dose Phase III clinical trial programme for OCREVUS® (ocrelizumab) and a distinct O CREVUS trial specifically to support African-American and Hispanic- and Latinx-American patients with MS. Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTR...
Source: Roche Investor Update - September 9, 2020 Category: Pharmaceuticals Source Type: news

Radiological Case: Odontogenic Ghost Cell Carcinoma Radiological Case: Odontogenic Ghost Cell Carcinoma
What was the origin of this 10-year-old patient's oral pain and swelling that had been worsening for approximately 1 week? Review the imaging studies in this unusual case.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 8, 2020 Category: Radiology Tags: Radiology Journal Article Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Media News - September 7, 2020 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Gavreto (pralsetinib) for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer
             Basel, 7 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto ™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verifica...
Source: Roche Investor Update - September 7, 2020 Category: Pharmaceuticals Source Type: news

NIDCR's Fall 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructu...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news

MASCC/ISOO Update Guidelines for Management of Mucositis
MONDAY, Aug. 31, 2020 -- The Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO) have issued updated recommendations for the management of mucositis; a summary of these updates was... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2020 Category: Pharmaceuticals Source Type: news

Consumer Health: Coping with mouth sores caused by cancer treatment
Certain cancer treatments can cause mouth sores that can be painful and distressing. They also can make it difficult for your mouth to heal itself and fend off germs, leading to infections. Chemotherapy and radiation -- alone or combined -- can cause mouth sores. That's because these cancer treatments are intended to kill rapidly growing [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 24, 2020 Category: Databases & Libraries Source Type: news

Robotic surgery may improve outcomes in mouth and throat cancer
(Cedars-Sinai Medical Center) Robotic surgery for patients with early stage, oropharyngeal squamous cell cancer is associated with improved health outcomes, including better long-term survival, according to a Cedars-Sinai study published Thursday in JAMA Oncology. Oropharyngeal cancer occurs in the back of the throat and includes the base of the tongue and tonsils. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 20, 2020 Category: Cancer & Oncology Source Type: news

An orally available non-nucleotide STING agonist with antitumor activity
Pharmacological activation of the STING (stimulator of interferon genes)–controlled innate immune pathway is a promising therapeutic strategy for cancer. Here we report the identification of MSA-2, an orally available non-nucleotide human STING agonist. In syngeneic mouse tumor models, subcutaneous and oral MSA-2 regimens were well tolerated and stimulated interferon-β secretion in tumors, induced tumor regression with durable antitumor immunity, and synergized with anti–PD-1 therapy. Experimental and theoretical analyses showed that MSA-2 exists as interconverting monomers and dimers in solution, but only...
Source: ScienceNOW - August 20, 2020 Category: Science Authors: Pan, B.-S., Perera, S. A., Piesvaux, J. A., Presland, J. P., Schroeder, G. K., Cumming, J. N., Trotter, B. W., Altman, M. D., Buevich, A. V., Cash, B., Cemerski, S., Chang, W., Chen, Y., Dandliker, P. J., Feng, G., Haidle, A., Henderson, T., Jewell, J., K Tags: Medicine, Diseases, Online Only r-articles Source Type: news

New gene therapy approach eliminates at least 90% latent herpes simplex virus 1
(Fred Hutchinson Cancer Research Center) Infectious disease researchers at Fred Hutchinson Cancer Research Center have used a gene editing approach to remove latent herpes simplex virus 1, or HSV-1, also known as oral herpes. In animal models, the findings show at least a 90 percent decrease in the latent virus, enough researchers expect that it will keep the infection from coming back. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 18, 2020 Category: Infectious Diseases Source Type: news

Gum Disease Tied to Colon Cancer Risk
People with periodontal disease had a higher risk of polyps that can lead to colon cancer. (Source: NYT Health)
Source: NYT Health - August 12, 2020 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Colon and Colorectal Cancer Gums (Mouth) Source Type: news

Bacterial invaders drive CRC progression
The oral bacterium Fusobacterium nucleatum is often found in colorectal cancer (CRC). In the 21 July 2020 issue of Science Signaling, Casasanta et al. show that CRC cell–resident F. nucleatum promotes cytokine secretion that may potentiate tumor growth and metastatic progression in patients. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 11, 2020 Category: Science Authors: Meyerson, M. Tags: STKE Focus Source Type: news

Science Saturday: Seeking a regenerative therapy for chronic dry mouth
Mayo Clinic researchers are seeking a regenerative therapy for a vexing problem, particularly among cancer patients. How can medical providers treat a condition in which the mouth is so parched that it has an incessant feeling of a cotton lining? Xerostomia, also known as chronic dry mouth, is an agonizing side effect of injury to the salivary [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 8, 2020 Category: Databases & Libraries Source Type: news

NHS rolls out'COVID-friendly' cancer treatments, NHS England
NHS England has earmarked £ 160 million to fund 50 treatments approved as'swaps'for existing drugs to reduce adverse effects, to take as oral medication at home, or as an alternative to hospital treatment. Covid-secure cancer hubs have also been set up to safely provide surgery. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 4, 2020 Category: Consumer Health News Source Type: news

Skin cancer symptoms: The sign in your mouth that could signal the deadly disease
SKIN CANCER - there's a certain type of skin cancer that can be caught by an infection with a virus. The first sign of the disease appears in the mouth. Here's what to look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - August 1, 2020 Category: Consumer Health News Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Media News - July 31, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Investor Update - July 31, 2020 Category: Pharmaceuticals Source Type: news

Mouth cancer symptoms: Have you had this 'persistent' problem in your mouth? Warning sign
MOUTH cancer has a high chance of being cured if caught early enough. Unfortunately, the coronavirus pandemic may have stopped some people getting their symptoms checked out - here's a persistent warning sign to look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - July 30, 2020 Category: Consumer Health News Source Type: news

Clinical trial tests oral cancer drug to combat respiratory symptoms of COVID-19
(Ohio State University Wexner Medical Center) Researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 29, 2020 Category: Cancer & Oncology Source Type: news

How airway cells work together in regeneration and aging
Researchers at theEli and Edythe Broad Center of  Regenerative Medicine and Stem Cell Research at UCLA have identified the process by which stem cells in the airways of the lungs switch between two distinct phases — creating more of themselves and producing mature airway cells — to regenerate lung tissue after an injury.The study, published in Cell Stem Cell, also sheds light on how aging can cause lung regeneration to go awry, which can lead to lung cancer and other diseases.  “There currently are few therapies that target the biology of lung diseases,” said Dr. Brigitte Gomperts,a profes...
Source: UCLA Newsroom: Health Sciences - July 27, 2020 Category: Universities & Medical Training Source Type: news

A change to the zodiac? This should never have been written into the stars
There has been a lot of talk about the Ophiuchus constellation joining the zodiac, but I won ’t be changing my Cancerian waysI am zodiac person. I have five books on the zodiac (and am open to many more). When I meet someone, before they have even opened their mouth I ’ll be trying to figure out what their star sign is. I’m not so into this stuff that I’ll dislike or avoid certain signs, but saying this, we all know that Gemini men are terrible.Lots of peoplearen ’tstar sign people, so to get around that one of the first questions I ask, as casually as possible, is when their birthday is. If t...
Source: Guardian Unlimited Science - July 25, 2020 Category: Science Authors: Candice Carty-Williams Tags: Books Astronomy Space Culture Source Type: news

Inside the Global Quest to Trace the Origins of COVID-19 —and Predict Where It Will Go Next
It wasn’t greed, or curiosity, that made Li Rusheng grab his shotgun and enter Shitou Cave. It was about survival. During Mao-era collectivization of the early 1970s, food was so scarce in the emerald valleys of southwestern China’s Yunnan province that farmers like Li could expect to eat meat only once a year–if they were lucky. So, craving protein, Li and his friends would sneak into the cave to hunt the creatures they could hear squeaking and fluttering inside: bats. Li would creep into the gloom and fire blindly at the vaulted ceiling, picking up any quarry that fell to the ground, while his companion...
Source: TIME: Health - July 23, 2020 Category: Consumer Health News Authors: Charlie Campbell/ Yuxi, Yunnan and Alice Park Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Bacteria that causes tooth decay might also help colon cancer spread, researchers say
The bacteria in the mouth that causes tooth decay might also help colon cancer spread to other organs in the body, according to a study published Tuesday by the journal Science Signaling. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 21, 2020 Category: Consumer Health News Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry  have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminate...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news

Cinnamon May Slow Progression To Type 2 Diabetes, Boston Study Finds
(CNN) — Cinnamon may improve blood sugar control in people with a condition known as prediabetes and may slow the progression to type 2 diabetes, according to a new pilot study of 51 people with elevated blood sugars. “We are looking for safe, durable and cost-effective approaches to reduce the progression from prediabetes to type 2 diabetes,” said study author Dr. Giulio Romeo, a staff physician at Boston’s Joslin Diabetes Center and the division of endocrinology at Beth Israel Deaconess Medical Center. The study published Tuesday in the Journal of the Endocrine Society. “Our 12-week study sh...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 21, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Cinnamon CNN Diabetes Source Type: news

Periodontal Disease, Tooth Loss Linked to Esophageal, Gastric Cancer
TUESDAY, July 21, 2020 -- Periodontal disease and tooth loss, indicative of oral microbial dysbiosis, are associated with esophageal and gastric adenocarcinoma, according to a research letter published online July 20 in Gut. Chun-Han Lo, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 21, 2020 Category: Pharmaceuticals Source Type: news

Virginia Tech researchers discover that mouth bacterium may cause colon cancer to spread
(Virginia Tech) Virginia Tech researchers have discovered that one of these common bacteria can leave the mouth and potentially cause existing cancer cells in other parts of the body to spread. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news

Not brushing your teeth increases chance of developing mouth and stomach cancer
A history of gum disease has been linked with an increase in the chance of developing cancer of the mouth and stomach, research from in Boston has found. (Source: the Mail online | Health)
Source: the Mail online | Health - July 21, 2020 Category: Consumer Health News Source Type: news

What Are Some Pediatric Oncological Emergencies?
Discussion Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other t...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

8.8 cr footfall recorded at health and wellness centres under Ayushman Bharat since Feb 1
In the last five months, 1.41 crore individuals were screened for hypertension, 1.13 crore for diabetes and 1.34 crore for oral, breast or cervical cancer, the ministry said. Despite the challenges posed by the COVID-19 pandemic, medicines were dispensed to about 5.62 lakh hypertension patients and 3.77 lakh diabetes patients at the HWCs in June alone, according to the statement. (Source: The Economic Times)
Source: The Economic Times - July 10, 2020 Category: Consumer Health News Source Type: news

FDA Approves Oral Treatment for Myelodysplastic Syndrome
Title: FDA Approves Oral Treatment for Myelodysplastic SyndromeCategory: Health NewsCreated: 7/8/2020 12:00:00 AMLast Editorial Review: 7/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 9, 2020 Category: Cancer & Oncology Source Type: news

T1 mapping shows promise for assessing neuroblastoma
The common MRI technique called T1 mapping -- typically used for patients with...Read more on AuntMinnie.comRelated Reading: Imaging shows new, post-SARS-CoV-2 illness in children Preop MRI finds 11% more cancer in women with DCIS PET, MRI uncover women's predisposition to Alzheimer's Imaging reveals baby girl in SC born with 2nd mouth Caution indicated with new GBCAs for kidney patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 1, 2020 Category: Radiology Source Type: news

School HPV vaccine policies could result in higher vaccination rates, reduction in cancers
FINDINGSA UCLA-led study has found that in 2 of 3 states and jurisdictions with policies that require students entering school to receive the human papillomavirus vaccine, vaccination rates among 13-to-17-year-olds were significantly higher than in surrounding states without such policies.In Rhode Island, the vaccination rate among adolescents was 91%, compared with an average of 78% in neighboring non-policy states. In the District of Columbia, the rate was 89%, compared with 72% for nearby non-policy states. Virginia, which is in the same region as the district, was the one state with a vaccination policy that showed no ...
Source: UCLA Newsroom: Health Sciences - June 29, 2020 Category: Universities & Medical Training Source Type: news

Coronavirus Could Upend Cancer Trends in the U.S.
Liz Satterfield has a ritual for every time she returns home after leaving the house. Diagnosed with metastatic breast cancer in 2016, the Kirkland, Washington resident recently learned that the cancer that had spread to her brain in 2018 was still growing. Throughout the pandemic, she’s had to visit the hospital at least once every three weeks, often more frequently, for treatments to control her disease. “I have a pair of shoes in a paper bag that I keep in the trunk of my car or a rack in the garage. I only wear those shoes when I’m going in to get treatment,” she says. “When I come home, I...
Source: TIME: Health - June 29, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Oral cancer: Do you have symptoms? New technology could detect disease at an early stage
ORAL cancer is a tumour that can develop on the tongue, the insides of the cheeks, the roof of the mouth, the lips or gums. Scientists are now working on a pain-free device that'll detect the disease in the early stages. (Source: Daily Express - Health)
Source: Daily Express - Health - June 27, 2020 Category: Consumer Health News Source Type: news

Imaging reveals baby girl in SC born with 2nd mouth
Imaging, specifically MRI and CT, helped clinicians determine that a mass located...Read more on AuntMinnie.comRelated Reading: Conebeam CT aids removal of rare ectopic molar in maxillary sinus CT confirms 3-cm swallowed dental needle in patient's neck Doctors find dentures in man's throat 8 days after surgery 3-month PET/CT helps track oropharyngeal cancer US-guided core biopsy best for salivary gland tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 23, 2020 Category: Radiology Source Type: news

Oncotarget: Bacteriome and mycobiome and bacteriome-mycobiome interactions
(Impact Journals LLC) Volume 11 Issue 25 of @Oncotarget reported that the authors aimed to characterize the bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma, or HNSCC, patients and to determine if they are distinct from those of the oral wash of matched non-Head and neck squamous cell carcinoma patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 23, 2020 Category: Cancer & Oncology Source Type: news